3 min read
Global Spotlight Shines on mRNA Thanks to Pfizer, BioNTech COVID-19 Vaccine Candidate
By Debra Valsamis on 11/11/2020
In the science shot heard ‘round the world, Pfizer and BioNTech announced Monday that their vaccine candidate (aka “BNT162b2”) appears to be more than 90% effective in preventing SARS-CoV-2 among those without evidence of prior infection. And since that news broke on the same day that the number of confirmed U.S. cases of COVID-19 crossed yet another grim threshold — 10 million infected — it couldn’t have come at a better time.
Topics: Insights Covid SARS-CoV-2 COVID-19 mRNA
Filter by Keyword
- Insights (32)
- COVID-19 (14)
- Covid (14)
- SARS-CoV-2 (14)
- Events (12)
- Molecuar Modeling (9)
- News (9)
- Transgenic Animals (5)
- antibody discovery (4)
- Therapeutic Targets (3)
- 25th Anniversary (2)
- Omicron (2)
- therapeutic monoclonal antibodies (2)
- ADC (1)
- Antibody-Drug Conjugate (1)
- CAR-T (1)
- Cell therapy (1)
- Functional Assays (1)
- Harbour (1)
- Hybridoma (1)
- IgG purification (1)
- Lambda Mouse (1)
- MAbExpress (1)
- Monoclonal (1)
- OmniRat (1)
- antigen (1)
- cell fusion (1)
- igG (1)
- immunoassays (1)
- immunogens (1)
- lambda light chain (1)
- mRNA (1)
- peptides (1)
- syngeneic (1)
- target analysis (1)
- transgenic H2L2 mice (1)
- women in bio (1)